{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:07:08Z","timestamp":1791662828204,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Zhuhai Livzon Cynvenio Diagnostics Ltd"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.clbc.2018.10.009","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T20:29:15Z","timestamp":1541104155000},"page":"e239-e246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer"],"prefix":"10.1016","volume":"19","author":[{"given":"Weirong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juncheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingming","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuoji","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2018.10.009_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pneumo.2013.07.001","article-title":"[Lymphatic spread of lung cancer: anatomical lymph node chains unchained in zones]","volume":"70","author":"Riquet","year":"2014","journal-title":"Rev Pneumol Clin"},{"key":"10.1016\/j.clbc.2018.10.009_bib2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","article-title":"Cancer metastasis: building a framework","volume":"127","author":"Gupta","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.clbc.2018.10.009_bib3","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1073\/pnas.95.8.4589","article-title":"Detection and characterization of carcinoma cells in the blood","volume":"95","author":"Racila","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clbc.2018.10.009_bib4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrc1098","article-title":"The pathogenesis of cancer metastasis: the \u2018seed and soil\u2019 hypothesis revisited","volume":"3","author":"Fidler","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clbc.2018.10.009_bib5","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.clbc.2018.10.009_bib6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10549-017-4138-3","article-title":"Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer","volume":"162","author":"Iwata","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2018.10.009_bib7","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.12659\/MSM.903736","article-title":"Predictive value of circulating tumor cells for evaluating short- and long-term efficacy of chemotherapy for breast cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.clbc.2018.10.009_bib8","author":"US Food & Drug Administration"},{"key":"10.1016\/j.clbc.2018.10.009_bib9","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.5858\/133.9.1468","article-title":"Circulating tumor cells from well-differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type","volume":"133","author":"Marrinucci","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clbc.2018.10.009_bib10","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1158\/0008-5472.CAN-08-3667","article-title":"Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2018.10.009_bib11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-012-2045-1","article-title":"Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study","volume":"134","author":"Pestrin","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2018.10.009_bib12","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/annonc\/mdy211","article-title":"Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial","volume":"29","author":"Ignatiadis","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2018.10.009_bib13","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.2147\/OTT.S118502","article-title":"A\u00a0FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation","volume":"9","author":"Frithiof","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clbc.2018.10.009_bib14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12885-016-2578-5","article-title":"Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients","volume":"16","author":"Zhang","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2018.10.009_bib15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12282-014-0539-x","article-title":"Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced\/metastatic breast cancer","volume":"23","author":"Shiomi-Mouri","year":"2016","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clbc.2018.10.009_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.lungcan.2014.05.002","article-title":"Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer","volume":"85","author":"Normanno","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clbc.2018.10.009_bib17","doi-asserted-by":"crossref","first-page":"43464","DOI":"10.1038\/srep43464","article-title":"Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis","volume":"7","author":"Yan","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clbc.2018.10.009_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trsl.2017.04.002","article-title":"Current approaches for avoiding the limitations of circulating tumor cells detection methods-implications for diagnosis and treatment of patients with solid tumors","volume":"185","author":"Kowalik","year":"2017","journal-title":"Transl Res"},{"key":"10.1016\/j.clbc.2018.10.009_bib19","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/14737159.2016.1255144","article-title":"Improving the CellSearch(R) system","volume":"16","author":"Swennenhuis","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.clbc.2018.10.009_bib20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.7150\/thno.5195","article-title":"Detecting circulating tumor cells: current challenges and new trends","volume":"3","author":"Hong","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.clbc.2018.10.009_bib21","doi-asserted-by":"crossref","first-page":"e15624","DOI":"10.1371\/journal.pone.0015624","article-title":"HER2-positive circulating tumor cells in breast cancer","volume":"6","author":"Ignatiadis","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2018.10.009_bib22","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1158\/1078-0432.CCR-07-0419","article-title":"Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes","volume":"13","author":"Nakagawa","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2018.10.009_bib23","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1055\/s-0031-1280463","article-title":"Circulating tumor cells in early-stage breast cancer","volume":"71","author":"Hartkopf","year":"2011","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.clbc.2018.10.009_bib24","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/jnci\/djs478","article-title":"Circulating tumor cells in early-stage breast cancer","volume":"104","author":"Sinha","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2018.10.009_bib25","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S1470-2045(12)70336-4","article-title":"Circulating tumour cells in early breast cancer","volume":"13","author":"Nair","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2018.10.009_bib26","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1158\/1078-0432.CCR-05-2087","article-title":"HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients","volume":"12","author":"Wulfing","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2018.10.009_bib27","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1158\/1078-0432.CCR-09-2042","article-title":"Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial","volume":"16","author":"Riethdorf","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2018.10.009_bib28","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/s12885-015-1423-6","article-title":"The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients","volume":"15","author":"Wallwiener","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2018.10.009_bib29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature19328","article-title":"HER2 expression identifies dynamic\u00a0functional states within circulating breast cancer cells","volume":"537","author":"Jordan","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2018.10.009_bib30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.neo.2016.08.007","article-title":"Prognostic impact of HER2 and ER status of circulating tumor cells in metastatic breast cancer patients with a HER2-negative primary tumor","volume":"18","author":"Beije","year":"2016","journal-title":"Neoplasia"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820918305007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820918305007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:17:17Z","timestamp":1761513437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820918305007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1526820918305007"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2018.10.009","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2018.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}